Share this Page:
MiT family translocation renal cell carcinoma is a rare and aggressive subgroup of renal cell carcinoma (RCC), a type of kidney cancer. People with translocation RCC have high levels of a gene called c-MET. Translation RCC dos not respond well to treatment with targeted therapies or immunotherapies. However, the effectiveness of cabozantinib in these patients is unclear.
This real-world study included 52 patients with metastatic translocation RCC. Eleven (21.2%) patients were given cabozantinib as a first-line treatment, 15 (28.8%) as a second-line treatment, and 26 (50%) as a third-line or beyond treatment. Nearly a fifth of patients responded to treatment, including 2 complete responses and 7 partial responses. Stable disease was achieved in half of the patients.
The patients were followed-up for around 2 years, and the average time to when the treatment stopped working and the cancer started growing again was 6.8 months. Average overall survival time was 18.3 months.
This real-world study shows that cabozantinib is effective for people with translocation RCC, and has better outcomes than other targeted therapies snd immunotherapies that have been tested in these patients.